BiotechTube
Home/Pipeline/ITK inhibitor

ITK inhibitor

Atopic dermatitis

Pre-clinicalHit-to-Lead

Key Facts

Indication
Atopic dermatitis
Phase
Pre-clinical
Status
Hit-to-Lead
Company
Acellera

About Acellera

Acellera's mission is to transform drug discovery into a high-accuracy, computable task by developing algorithms that automate the process. Founded in 2016, the company has built a robust technology stack, including the QuantumBind® platform and open-source tools like ACEMD, OpenMM, and ACEGEN, backed by over 18 years of computational know-how and thousands of academic citations. While currently a private company with no external investment, Acellera is developing an internal pipeline of drug candidates and plans to raise funding in 2026 to scale its ambitious goals.

View full company profile

Therapeutic Areas

OncologyImmunologyInflammatory DiseasesInfectious DiseasesNeurology

Other Atopic dermatitis Drugs

DrugCompanyPhase
LebrikizumabEli LillyPhase 3
DupixentSanofiCommercial
ASP2408Astellas PharmaPhase 2
KW-6356Kyowa KirinPhase 2
KHK4083Kyowa KirinPhase 2
Opzelura (ruxolitinib cream)Ono PharmaceuticalApproved
ONO-7913Ono PharmaceuticalPhase 2
KT-474Kymera TherapeuticsPhase 2
GRC 27864Glenmark PharmaceuticalsPhase 2
ARQ-234Arcutis BiotherapeuticsPreclinical/Phase 1
STAR-0310BioCryst PharmaceuticalsPhase 1
RezpegaldesleukinNektar TherapeuticsPhase 2b